LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Abbott Laboratories

Suletud

SektorTervishoid

113.25 0.9

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

111.28

Max

113.37

Põhinäitajad

By Trading Economics

Sissetulek

-135M

1.6B

Müük

90M

11B

P/E

Sektori keskmine

30.29

110.024

Aktsiakasum

1.5

Dividenditootlus

2.15

Kasumimarginaal

14.46

Töötajad

115,000

EBITDA

-491M

2.5B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+22.15% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.15%

2.26%

Järgmine tulemuste avaldamine

15. apr 2026

Järgmine dividendimakse kuupäev

14. mai 2026

Järgmine aktsia dividendi kuupäev (ex-date)

14. apr 2026

Turustatistika

By TradingEconomics

Turukapital

-16B

196B

Eelmine avamishind

112.35

Eelmine sulgemishind

113.25

Uudiste sentiment

By Acuity

24%

76%

58 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Abbott Laboratories Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. jaan 2026, 18:36 UTC

Tulu
Suurimad hinnamuutused turgudel

Abbott Laboratories Raised Prices, Prompting Sales Slump -- Update

22. jaan 2026, 13:23 UTC

Tulu
Suurimad hinnamuutused turgudel

Abbott Laboratories 4Q Sales Grow, Outlook Underwhelms

20. nov 2025, 13:14 UTC

Omandamised, ülevõtmised, äriostud

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

20. nov 2025, 13:11 UTC

Omandamised, ülevõtmised, äriostud

Abbott to Acquire Exact Sciences for $21 Billion -- Update

28. jaan 2026, 14:48 UTC

Tulu

Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares. -- Barrons.com

23. jaan 2026, 16:59 UTC

Tulu

Correction to Abbott Stock Drops Article on Jan. 22

22. jaan 2026, 20:42 UTC

Tulu

Abbott Stock Is on Pace for Worst Day Since 2000. The Nutrition Business Is a Drag on Earnings. -- Barrons.com

22. jaan 2026, 16:19 UTC

Tulu

Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings. -- Barrons.com

22. jaan 2026, 15:22 UTC

Tulu

Abbott Stock Drops on Slumping Sales of Baby Formula and Nutrition Shakes -- WSJ

22. jaan 2026, 14:41 UTC

Kuumad aktsiad

Stocks to Watch Thursday: Intel, P&G, GE Aerospace -- WSJ

22. jaan 2026, 14:08 UTC

Market Talk
Tulu

Abbott Posts Disappointing 4Q -- Market Talk

22. jaan 2026, 12:49 UTC

Tulu

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Device Maker. -- Barrons.com

22. jaan 2026, 12:31 UTC

Tulu

Abbott Labs: Well Positioned for Accelerating Growth in 2026 >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs Sees 2026 Organic Sales Growth of 6.5%-7.5% >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs Sees 1Q Adj EPS $1.12-Adj EPS $1.18 >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs 4Q Net $1.78B >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs 4Q Sales $11.46B >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs Sees FY Adj EPS $5.55-Adj EPS $5.80 >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs 4Q Organic Sales Growth Up 3.0% >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs 4Q Adj EPS $1.50 >ABT

22. jaan 2026, 12:30 UTC

Tulu

Abbott Labs 4Q EPS $1.01 >ABT

20. nov 2025, 21:23 UTC

Tulu
Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. nov 2025, 16:51 UTC

Omandamised, ülevõtmised, äriostud

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

20. nov 2025, 15:08 UTC

Omandamised, ülevõtmised, äriostud

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

20. nov 2025, 14:39 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

20. nov 2025, 14:30 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

20. nov 2025, 13:54 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Palo Alto Networks, Alphabet, and More -- Barrons.com

20. nov 2025, 13:51 UTC

Omandamised, ülevõtmised, äriostud

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

20. nov 2025, 13:25 UTC

Omandamised, ülevõtmised, äriostud

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

20. nov 2025, 13:24 UTC

Omandamised, ülevõtmised, äriostud

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Abbott Laboratories Prognoos

Hinnasiht

By TipRanks

22.15% tõus

12 kuu keskmine prognoos

Keskmine 138.38 USD  22.15%

Kõrge 158 USD

Madal 122 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Abbott Laboratories 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

16

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

132.82 / 134.43Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

58 / 351 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat